Recombinant Mouse ECM1 protein (rFc Tag)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Mouse ECM1 protein (rFc Tag) (Eg2683)

Species

Mouse

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg2683

---

Validation Data Gallery

• 

  Purity of Recombinant Mouse ECM1 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Mouse ECM1 protein Ala20-Glu559 (Accession# Q61508-1) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 13601
• Accession: Q61508-1
• PredictedSize: 87.1 kDa
• SDS-PAGE: 100-120 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Extracellular matrix protein 1 (ECM1) is a glycoprotein involved in a number of biological processes such as bone formation, skin differentiation, cell proliferation, and promotes angiostasis.ECM1 is expressed in breast cancer and could participate in cell migration and angiogenesis. Pathologically, ECM1 contributes to the formation and metastasis of several types of cancer including breast, thyroid and hepatocellular cancers.(PMID:21128013) It inhibits MMP9 proteolytic activity. ECM1 protein is a possible trigger for angiogenesis, tumor progression and malignancies(PMID:21497598).

References:

1. Chen H. (2010). Med Oncol. 28 Suppl 1:S318-25. 
2. López-Marure R. et al. (2011). Eur J Pharmacol. 25;660(2-3):268-74.